| Study Number |
Title |
| 09-130-B |
A University of Chicago Leukemia Registry Protocol.
|
| 10-064-B |
Molecular characterization of hematopoietic malignancies
|
| 11-0027 |
A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy (V212-011)
|
| 11-0050 |
A Phase III, Multicenter, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine (Protocol 04-21).
|
| 11-0300 |
A Phase 1, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects with Intermediate or High-Risk
Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
|
| 11-0619 |
An open label assessment of safety and efficacy of Ruxolitinib (INCB018424) in subjects with primary myelofibrosis, post essential thrombocythemia-myelofibrosis and post polycythemia vera-myelofibrosis who have platelet counts of 50 x109/L to 100 x109/L.
|
| 11-0270 |
Pharmacokinetics, Safety and Tolerability of Intravenous Posaconazole Solution followed by Oral Posaconazole Suspension (SCH 56592) in Subjects at High Risk for Invasive Fungal Infections (Phase 1B) (P05520)
|
| 12-0153 |
A phase 1b study to evaluate the safety and preliminary efficacy of PF-04449913, an oral hedgehog inhibitor, in combination with intensive chemotherapy, low dose ara-C or decitabine in patients with acute myeloid leukemia or high risk myelodysplastic syndrome.
|
Bone